MARKET

SAVA

SAVA

Cassava Sciences
NASDAQ
2.850
0.000
0.00%
After Hours: 2.640 -0.21 -7.37% 19:58 12/18 EST
OPEN
2.900
PREV CLOSE
2.850
HIGH
2.970
LOW
2.840
VOLUME
708.99K
TURNOVER
--
52 WEEK HIGH
4.980
52 WEEK LOW
1.150
MARKET CAP
137.68M
P/E (TTM)
-1.2968
1D
5D
1M
3M
1Y
5Y
1D
Stocks to Watch: Nike, Cassava Sciences, KB Home
Dow Jones · 7h ago
Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial
Dow Jones · 7h ago
FDA Places Clinical Hold on Cassava’s Epilepsy Trial
TipRanks · 8h ago
On December 15, 2025, Cassava Sciences Received A Formal Letter From FDA Confirming That The Proposed Clinical Trial Is On Full Clinical Hold Subject To The Company Providing FDA With Additional Information
Benzinga · 8h ago
CASSAVA SCIENCES INC - ON DEC 15, FDA PLACES FULL CLINICAL HOLD ON CASSAVA'S TRIAL - SEC FILING
Reuters · 8h ago
CASSAVA SCIENCES: NOT EXPECTED TO INITIATE PROOF-OF-CONCEPT CLINICAL TRIAL FOR SIMUFILAM IN TSC-RELATED EPILEPSY IN H1 2026 AS PREVIOUSLY DISCLOSED
Reuters · 8h ago
FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold
Reuters · 9h ago
Cassava Sciences Approves Executive Cash Bonuses for 2025
TipRanks · 1d ago
More
About SAVA
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.